Topics

Opioid Dropped After Thumbs Down From FDA Advisory Panel

10:22 EST 15 Jan 2020 | Medscape

Following a unanimous vote by an FDA advisory panel against recommending approval of a new opioid, the company has withdrawn its NDA and announced it will make no further investment in the drug's development.
Medscape Medical News

Original Article: Opioid Dropped After Thumbs Down From FDA Advisory Panel

NEXT ARTICLE

More From BioPortfolio on "Opioid Dropped After Thumbs Down From FDA Advisory Panel"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...